These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17176613)

  • 1. Resolution of neurotoxicity and beta-cell toxicity in an islet transplant recipient following substitution of tacrolimus with MMF.
    Froud T; Baidal DA; Ponte G; Ferreira JV; Ricordi C; Alejandro R
    Cell Transplant; 2006; 15(7):613-20. PubMed ID: 17176613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation.
    Roelen DL; Huurman VA; Hilbrands R; Gillard P; Duinkerken G; van der Meer-Prins PW; Versteeg-van der Voort Maarschalk MF; Mathieu C; Keymeulen B; Pipeleers DG; Roep BO; Claas FH
    Clin Exp Immunol; 2009 Apr; 156(1):141-8. PubMed ID: 19161445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets.
    Johnson JD; Ao Z; Ao P; Li H; Dai LJ; He Z; Tee M; Potter KJ; Klimek AM; Meloche RM; Thompson DM; Verchere CB; Warnock GL
    Cell Transplant; 2009; 18(8):833-45. PubMed ID: 19500470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal.
    Heilman RL; Younan K; Wadei HM; Mai ML; Reddy KS; Chakkera HA; Gonwa TA
    Transplantation; 2011 Oct; 92(7):767-73. PubMed ID: 21775930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation.
    Jiménez-Pérez M; González Grande R; Rando Muñoz FJ; de la Cruz Lombardo J; Muñoz Suárez MA; Fernández Aguilar JL; Pérez Daga JA; Santoyo-Santoyo J; Manteca González R; Rodrigo López JM
    Transplant Proc; 2015; 47(1):90-2. PubMed ID: 25645779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient.
    Kaplan B; West P; Neeley H; Martellotto J; Iqbal R; Gangemi A; Hatipoglu B; Benedetti E; Oberholzer J
    Clin Transplant; 2008; 22(2):250-3. PubMed ID: 18339148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients.
    Kandula P; Fridell J; Taber TE; Sharfuddin A; Yaqub MS; Phillips CL; Chen J; Mujtaba M
    Transplantation; 2012 Nov; 94(9):940-6. PubMed ID: 23037007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus.
    Pratap B; Abraham G; Srinivas CN; Bhaskar S
    Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):609-12. PubMed ID: 17951952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
    Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
    Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of glucocorticoid-free immunosuppressive regimen in allogenic islet transplantation.
    Du CY; Xu EK
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):43-7. PubMed ID: 16481281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression.
    Lee D; Keymeulen B; Hilbrands R; Ling Z; Van de Velde U; Jacobs-Tulleneers-Thevissen D; Maleux G; Lapauw B; Crenier L; De Block C; Mathieu C; Pipeleers D; Gillard P
    Transplantation; 2017 Sep; 101(9):2218-2227. PubMed ID: 27779572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression.
    Nijhoff MF; Engelse MA; Dubbeld J; Braat AE; Ringers J; Roelen DL; van Erkel AR; Spijker HS; Bouwsma H; van der Boog PJ; de Fijter JW; Rabelink TJ; de Koning EJ
    Am J Transplant; 2016 Jan; 16(1):246-53. PubMed ID: 26288226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes.
    O'Connell PJ; Holmes-Walker DJ; Goodman D; Hawthorne WJ; Loudovaris T; Gunton JE; Thomas HE; Grey ST; Drogemuller CJ; Ward GM; Torpy DJ; Coates PT; Kay TW;
    Am J Transplant; 2013 Jul; 13(7):1850-8. PubMed ID: 23668890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary effects of immunosuppressive drugs after simultaneous pancreas-kidney transplantation.
    Kuypers DR; Malaise J; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii33-9, ii62. PubMed ID: 15814548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.